Oral Oncology
Volume 36, Issue 1 , Pages 54-60 , January 2000

Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients

  • I.M Dijkema

      Affiliations

    • Department of Radiotherapy, University Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-30-2508800; fax: +31-30-2581226
    • ,
  • H Struikmans

      Affiliations

    • Department of Radiotherapy, University Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands
    • ,
  • H.F.J Dullens

      Affiliations

    • Department of Pathology, University Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands
    • ,
  • H.B Kal

      Affiliations

    • Department of Radiotherapy, University Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands
    • ,
  • I van der Tweel

      Affiliations

    • Centre for Biostatistics, Padualaan 14, 3584 CH Utrecht, Netherlands
    • ,
  • J.J Battermann

      Affiliations

    • Department of Radiotherapy, University Hospital Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands

Received 11 May 1999 ,Accepted 22 June 1999.

References 

  1. Gasparini G, Bevilacqua P, Bonoldi E, et al.  Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clinical Cancer Research. 1995;1:1375–1383
  2. Struikmans H, Rutgers DH, Hordijk GJ, et al.  Prognostic significance of cell proliferation markers and DNA-ploidy in head and neck tumors. International Journal of Radiation Oncology, Biology, Physics. 1998;40:27–34
  3. Wilson GD, Grover R, Richman PI, et al.  Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Research. 1996;16:2403–2408
  4. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology. 1996;41:31–39
  5. Horiot JC, Bontemps P, van den Bogaert W, et al.  Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radio-therapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiotherapy and Oncology. 1997;44:111–121
  6. Withers HR, Taylor JM, Maciejeski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncology. 1988;27:131–146
  7. Begg AC, Haustermans K, Hart AAM, et al.  The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiotherapy and Oncology. 1999;50:13–23
  8. Friedman M, et al.  Prognostic significance of bcl-2 expression in localized squamous cell carcinoma of the head and neck. Annals of Otology, Rhinology and Laryngology. 1997;106:445–450
  9. Wilson GD, Richman PI, Dische S, et al.  P53 status of head and neck cancer: relation to biological characteristics and outcome in radiotherapy. British Journal of Cancer. 1995;71:1248–1252
  10. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer. 1994;73:2013–2026
  11. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiotherapy and Oncology. 1996;40:197–223
  12. Goodger NM, Gannon J, Hunt T, Morgan PR. Cell cycle regulatory proteins—an overview with relevance to oral cancer. Oral Oncology. 1997;33:61–73
  13. Yarnold J. Molecular aspects of cellular responses to radiotherapy. Radiotherapy and Oncology. 1997;44:1–7
  14. Hill ME, MacLennan KA, Cunningham DC, et al.  Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation study. Blood. 1996;88:1046–1051
  15. Silvestrini R, Veneroni S, Daidone MG, et al.  The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. Journal of the National Cancer Institute. 1994;86:499–504
  16. Watson AJ, Merrit AJ, Lones LS, et al.  Evidence for reciprocity of bcl-2 and p53 expression in human clorectal adenomas and carcinomas. British Journal of Cancer. 1996;74:889–895
  17. Hale AJ, Smith CA, Sutherland LC, et al.  Apoptosis: molecular regulation of cell death. European Journal of Biochemistry. 1996;236:1–26
  18. Borner C. Diminished cell proliferation associated with the death-protective activity of bcl-2. The Journal of Biological Chemistry. 1996;271:12695–12698
  19. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. Journal of Experimental Medicine. 1996;183:2219–2226
  20. Salo A, Servomaa K, Kiuru A, et al.  The bcl-2 gene status of human head and neck cancer cell lines. Acta Otolaryngologica (Stockholm). 1997;529(Suppl.):233–236
  21. Pellegata NS, Antoniono RJ, Redpath JL, et al.  DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proceedings of the National Academy of Sciences USA. 1996;93:15209–15214
  22. Servomaa K, Kiuri A, Grénman R, et al.  P53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Proliferation. 1996;29:219–230
  23. Tan LK, Ogden GR. P53 over-expression in laryngeal carcinoma is not predictive of response to radiotherapy. Oral Oncology. 1997;33:177–181
  24. Gallo O, Boddi V, Calzolari A, et al.  Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clinical Cancer Research. 1996;2:261–267
  25. Veneroni S, Silvestrini R, Costa A, et al.  Biological indicators of survival in patients treated by surgery for squamous cell carcinoma of the oral cavity and oropharynx. Oral Oncology. 1997;33:408–413
  26. Bourish J, Bosq J, Wilson GD, et al.  Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer. International Journal of Cancer. 1994;57:458–462
  27. Schutte B, Reynderd MM, van Assche CL, et al.  An improved method for the immunocytochemical detection of bromodeoxyuridine labelled nuclei using flow cytometry. Cytometry. 1987;8:372–376
  28. Van der Linden PM. An iterative method of analysis for DNA histograms. Acta Pathologica et Microbiologica Scandinavica. 1981;274(Suppl.):133–137
  29. Beck HP. Evaluation of flow cytometric data of human tumours. Correction procedures for background and cell aggregations. Cell Tissue Kinetics. 1980;13:173–181
  30. Begg AC, McNally NJ, Shrieve DC. A method to measure the duration of the DNA synthesis and the potential volume doubling time from a single sample. Cytometry. 1985;6:620–626
  31. Jin Y, Kayser S, Kemp BL, et al.  The prognostic significance of the biomarkers p21, p53, and bcl-2 in laryngeal squamous cell carcinoma. Cancer. 1998;82:2159–2165
  32. Narayana A, Vaughan AT, Gunaratne S, et al.  Is p53 an independent prognostic factor in patients with laryngeal carcinoma?. Cancer. 1998;82:286–291
  33. Kropveld A, Leppers FG, Scheidel CC et al. Beyond the p53 core domain: towards 100% concordance between immunohistochemical findings and gene mutations. In: Kropveld A, editor. P53 in Diagnosis and Treatment of Head and Neck Cancer. Utrecht, 1998. p. 123–136.
  34. Cayrol C, Knibiehler M, Ducommun B. P21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998;16:311–320
  35. Pietenpol JA, Papadopoulos N, Markowitz S, et al.  Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Research. 1994;54:3714–3717

PII: S1368-8375(99)00051-2

Oral Oncology
Volume 36, Issue 1 , Pages 54-60 , January 2000

Article Tools

* Image Usage & Resolution